TWI692357B - 新穎之使用方法 - Google Patents

新穎之使用方法 Download PDF

Info

Publication number
TWI692357B
TWI692357B TW104141446A TW104141446A TWI692357B TW I692357 B TWI692357 B TW I692357B TW 104141446 A TW104141446 A TW 104141446A TW 104141446 A TW104141446 A TW 104141446A TW I692357 B TWI692357 B TW I692357B
Authority
TW
Taiwan
Prior art keywords
compound
stilbene
dihydroxy
trans
isopropyl
Prior art date
Application number
TW104141446A
Other languages
English (en)
Chinese (zh)
Other versions
TW201639548A (zh
Inventor
賈維爾 寇特席耶拉
蘇珊 史密斯
史蒂芬 佛瑞
Original Assignee
瑞士商德瑪凡特科學有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商德瑪凡特科學有限公司 filed Critical 瑞士商德瑪凡特科學有限公司
Publication of TW201639548A publication Critical patent/TW201639548A/zh
Application granted granted Critical
Publication of TWI692357B publication Critical patent/TWI692357B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW104141446A 2014-12-12 2015-12-10 新穎之使用方法 TWI692357B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462090908P 2014-12-12 2014-12-12
US62/090,908 2014-12-12

Publications (2)

Publication Number Publication Date
TW201639548A TW201639548A (zh) 2016-11-16
TWI692357B true TWI692357B (zh) 2020-05-01

Family

ID=55025296

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104141446A TWI692357B (zh) 2014-12-12 2015-12-10 新穎之使用方法

Country Status (11)

Country Link
US (1) US10376475B2 (enExample)
EP (1) EP3229840B1 (enExample)
JP (3) JP7313117B2 (enExample)
KR (1) KR102607222B1 (enExample)
AR (1) AR102973A1 (enExample)
AU (1) AU2015358910B2 (enExample)
CA (1) CA2970739C (enExample)
DK (1) DK3229840T5 (enExample)
ES (1) ES2829637T3 (enExample)
TW (1) TWI692357B (enExample)
WO (1) WO2016092493A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
IL316851A (en) 2015-05-21 2025-01-01 Dermavant Sciences GmbH Preparations that are pharmaceutical emulsions for topical use containing 5,3-dihydroxy-4-isopropyl-trans-stilbene and their use for the treatment or prevention of dermatological conditions or disorders
US20170231922A1 (en) * 2016-02-16 2017-08-17 Horizon GenoMed Therapeutics, Inc 3, 5-dihydroxy-4-isopropylstilbene (dhis) as miticidal agent and its therapeutic uses
CA3082115A1 (en) 2017-11-10 2019-05-16 Dermavant Sciences GmbH Process for preparing tapinarof
US10967197B2 (en) 2018-08-29 2021-04-06 Azulite, Inc. Phototherapy devices and methods for treating truncal acne and scars
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
WO2020174467A1 (en) * 2019-02-25 2020-09-03 Sol-Gel Technologies Ltd. Treatment of psoriasis with topical tapinarof- tazarotene combination compositions
US20220202737A1 (en) * 2019-03-26 2022-06-30 Sol-Gel Technologies Ltd. Treatment of hidradenitis suppurativa with tapinarof compositions
WO2021014453A1 (en) * 2019-07-24 2021-01-28 Sol-Gel Technologies Ltd. Topical jak inhibitor combination compositions for treatment of inflammatory skin conditions
WO2021059281A1 (en) * 2019-09-26 2021-04-01 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical combination compositions comprising tapinarof and an additional ahr activator
EP4061332A4 (en) * 2019-11-24 2023-11-29 Sol-Gel Technologies Ltd. TREATMENT OF SKIN DISEASES USING TOPICAL COMPOSITIONS CONTAINING TAPINAROF AND A PDE4 INHIBITOR
WO2023109859A1 (zh) * 2021-12-15 2023-06-22 上海泽德曼医药科技有限公司 二苯乙烯类化合物及其在用于预防和/或治疗中枢神经系统相关疾病中的应用
CN116265421B (zh) * 2021-12-17 2024-01-02 上海泽德曼医药科技有限公司 用于预防或治疗中枢神经系统相关疾病的化合物
JP2025529076A (ja) * 2022-08-30 2025-09-04 ダーマヴァント サイエンシーズ ゲーエムベーハー ＡｈＲ媒介疾患の治療に使用するタピナロおよびそのアナログ製剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059733A1 (en) * 1999-12-06 2005-03-17 Welichem Biotech, Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7513994A (en) 1993-07-27 1995-02-28 Agro-Biotech Corporation Novel fungicidal properties of metabolites, culture broth, stilbene derivatives and indole derivatives produced by the bacteria (xenorhabdus) and (photorhabdus) spp.
US5747482A (en) * 1996-07-30 1998-05-05 Bernstein; Lawrence R. Methods and compositions to inhibit keratinocyte proliferation
ATE444960T1 (de) 1999-12-06 2009-10-15 Welichem Biotech Inc Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
AU2003271470B2 (en) * 2002-10-01 2010-03-18 Welichem Biotech Inc. Novel bioactive diphenyl ethene compounds and their therapeutic applications
FR2917427B1 (fr) * 2007-06-18 2009-08-21 Galderma Res & Dev Inhibiteurs de tace dans le traitement de l'acne
WO2009108762A2 (en) * 2008-02-26 2009-09-03 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
US20100003315A1 (en) * 2008-07-02 2010-01-07 Willeford Kenneth L Method and Composition for the Treatment of Skin Conditions
CN101531571B (zh) 2009-04-17 2013-03-20 河北科技大学 六次甲基四胺氧化合成二苯乙烯类化合物的方法
CN101633606B (zh) 2009-08-13 2014-08-27 河北科技大学 盐酸非均相氯代合成茋类化合物的方法
CN101648851B (zh) 2009-09-03 2012-10-10 河北科技大学 (e)-3,5-二羟基-4-异丙基二苯乙烯的清洁制备方法
CN101830764A (zh) 2010-05-05 2010-09-15 河北科技大学 利用Pfitzner-moffatt氧化反应合成茋类化合物的方法
CN101838173A (zh) 2010-05-07 2010-09-22 河北科技大学 利用Kornblum氧化反应合成茋类化合物的方法
BR112013033617B1 (pt) * 2011-06-27 2021-10-26 Galderma Research & Development Uso de mrna, método para o diagnóstico de acne, métodos para o monitoramento da progressão ou variação de acne e da eficácia de um tratamento para tratar acne, e de triagem in vitro para a identificação de inibidores de diferenciação de células th17

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059733A1 (en) * 1999-12-06 2005-03-17 Welichem Biotech, Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues

Also Published As

Publication number Publication date
JP7313117B2 (ja) 2023-07-24
DK3229840T5 (da) 2020-11-16
JP2023123554A (ja) 2023-09-05
JP2021152018A (ja) 2021-09-30
TW201639548A (zh) 2016-11-16
ES2829637T3 (es) 2021-06-01
KR20170095928A (ko) 2017-08-23
KR102607222B1 (ko) 2023-11-29
US10376475B2 (en) 2019-08-13
EP3229840B1 (en) 2020-09-09
AU2015358910A1 (en) 2017-06-29
AU2015358910B2 (en) 2019-01-24
WO2016092493A1 (en) 2016-06-16
US20170360719A1 (en) 2017-12-21
DK3229840T3 (da) 2020-11-09
EP3229840A1 (en) 2017-10-18
CA2970739A1 (en) 2016-06-16
AR102973A1 (es) 2017-04-05
JP2017537936A (ja) 2017-12-21
CA2970739C (en) 2023-10-03

Similar Documents

Publication Publication Date Title
EP3229840B1 (en) 3,5-dihydroxy-4-isopropyl-trans-stilbene for use in the topical treatment of acne
Demessant‐Flavigny et al. Skin microbiome dysbiosis and the role of Staphylococcus aureus in atopic dermatitis in adults and children: A narrative review
Bitschar et al. Staphylococcus aureus skin colonization is enhanced by the interaction of neutrophil extracellular traps with keratinocytes
JP6505594B2 (ja) プロバイオティクス細菌
CN108135947B (zh) 提高免疫应答和皮肤和/或粘膜屏障功能的材料和方法
Hendricks et al. Skin bacterial transplant in atopic dermatitis: Knowns, unknowns and emerging trends
WO2007011606A2 (en) USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
Jacobo-Delgado et al. Retinoic acid induces antimicrobial peptides and cytokines leading to Mycobacterium tuberculosis elimination in airway epithelial cells
Mertens et al. Azithromycin differentially affects the IL-13-induced expression profile in human bronchial epithelial cells
TWI840499B (zh) 皮膚疾患的預防、改善或治療用醫藥組成物
WO2020056359A1 (en) Bacteriotherapy against proprionibacterium acnes for the treatment of acne
OuYang et al. MAD ointment ameliorates Imiquimod-induced psoriasiform dermatitis by inhibiting the IL-23/IL-17 axis in mice
Urzua et al. Skin barrier dysfunction in chronic dermatoses: from pathophysiology to emerging therapeutic strategies
JP2002212100A (ja) ニキビ予防及び治療用スフィンゴ脂質組成物
US11759484B2 (en) Compositions and uses thereof
KR20250061733A (ko) 여드름 치료를 위한 푸소박테리움 뉴클레아툼
TW201711696A (zh) 用於促進傷口癒合的吳郭魚抗菌胜肽
Lee et al. Lipoteichoic acid as a key wound-healing mediator in Gram-positive bacteria
Lee et al. Successful Use of Adalimumab for Dissecting Cellulitis in a Pediatric Patient With Keratitis–Ichthyosis–Deafness (KID) Syndrome
Friedrich HIF-1α drives fungal immunity in human macrophages
Farfán Esquivel Interaction between Cutibacterium acnes, bacteriophages and keratinocytes as a study model of acne phage therapy
Esquivel Interaction between Cutibacterium acnes, bacteriophages and keratinocytes as a study model of acne phage therapy.
CN121512984A (zh) 富马酸及高产富马酸的头状葡萄球菌的用途
JP2016510809A (ja) 膣感染症の治療に使用するためのリファキシミン
JP2021525798A (ja) 抗アミロイドモノクローナル抗体を使用した細菌バイオフィルムの根絶